TofacitinibEffectiveness and Safety of Tofacitinib in Patients With Recalcitrant Frontal Fibrosing Alopecia : A Pilot Study

Study start date: November 29, 2023

Inclusion Criteria: 1. Thai males or females who were at least 18 years old 2. Participants who were diagnosed with frontal fibrosing alopecia The criteria for the diagnosis of frontal fibrosis alopecia are 2 major criteria or 1 major criterion plus 2 minor criteria. (Vañó-Galván et al., 2014) 3. Participants who were diagnosed with recalcitrant frontal fibrosing alopecia * The patient who fails treatment of at least one drug, such as hydroxychloroquine, and/or receives others, such as immunosuppressive drugs, pioglitazone, and retinoids. However, the symptoms of FFA still appear, such as perifollicular erythematous and/or scale, after taking treatment for more than 3 months * The patient continued taking the medicine as prescribed and coming to follow-up * The patient still has the medical record, such as a picture and dermoscopy * The patient does not need a washout time from the current medicine Exclusion Criteria: 1. Patients who were diagnosed with a disease that may relate to hair growth within six months, such as thyroid disease, iron deficiency anemia, liver disease, heart disease, neurological system disease, gastroenteritis disease, sexual disease, cancer, and psychologic disease 2. Pregnancy 3. Patients who have contraindications to take oral Tofacitinib such as severe infection, allergy to Tofacitinib, venous thromboembolism, leukopenia, severe liver disease, severe kidney failure, pneumonia, cancer 4. Patients who received strong or moderate to strong CYP3A4 agents 5. Patients who had positive on HBsAg and/or HCV